Cyclin-Dependent Kinases (CDK) and Their Role in Diseases Development–Review
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Cyclin-dependent kinases (CDKs) are involved in many crucial processes, such as cell cycle and transcription, as well as communication, metabolism, and apoptosis. The kinases are organized in a pathway to ensure that, during cell division, each cell accurately replicates its DNA, and ensure its segregation equally between the two daughter cells. Deregulation of any of the stages of the cell cycle or transcription leads to apoptosis but, if uncorrected, can result in a series of diseases, such as cancer, neurodegenerative diseases (Alzheimer’s or Parkinson’s disease), and stroke. This review presents the current state of knowledge about the characteristics of cyclin-dependent kinases as potential pharmacological targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S. M., Ahmad, M., Alnemri, E. S., & Wang, X. (1997) · Cell · doi:10.1016/s0092-8674(00)80434-1 · Cited by 7,289 · cited 1×
“Once in cytoplasm, cytochrome c binds to apoptotic protease activating factor 1 (Apaf-1), resulting in activation of caspase9 [247].”
BackgroundCDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
The retinoblastoma protein and cell cycle control
Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90385-2 · Cited by 4,862
Cell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957 · cited 1×
“This tightly controlled restriction point is regulated by CDK4/6 complex, which is further controlled by the regulatory subunits D-type cyclins (D1, D2 and D3) and CDK inhibitor p16INK4a ([34].”
BackgroundIntegrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645
Molecular Mechanisms of Mammalian DNA Repair and the DNA Damage Checkpoints
Sancar, A., Lindsey-Boltz, L. A., Ünsal-Kaçmaz, K., & Linn, S. (2004) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.73.011303.073723 · Cited by 3,317 · cited 1×
“P53 is also known to control the G2/M checkpoint, by interacting with CDK1/cycB to arrest passage of cells from G2 into mitosis [180].”
BackgroundTargeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788 · cited 1×
“For example, many cancers exhibit increased cyclin D levels, which leads to the activation of the RAS–RAF–MEK–ERK pathway, inter alia, by overexpression of the growth factor receptors or by inducing mutations in signaling effector proteins [214].”
BackgroundThe regulation of E2F by pRB-family proteins.
Dyson, N. (1998) · Genes & Development · doi:10.1101/gad.12.15.2245 · Cited by 2,317
Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy
Fulda, S., & Debatin, K.-M. (2006) · Oncogene · doi:10.1038/sj.onc.1209608 · Cited by 2,312
Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization
Diehl, J. A., Cheng, M., Roussel, M. F., & Sherr, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.22.3499 · Cited by 2,130
AACR Project GENIE: Powering Precision Medicine through an International Consortium
The AACR Project GENIE Consortium, The AACR Project GENIE Consortium, André, F., Arnedos, M., Baras, A. S., Baselga, J., Bedard, P. L., Berger, M. F., Bierkens, M., Calvo, F., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0151 · Cited by 1,964
Spliceosome Structure and Function
Will, C. L., & Luhrmann, R. (2011) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a003707 · Cited by 1,829 · cited 1×
“Nuclear pre-mRNA splicing is catalyzed by the spliceosome, a large and dynamic complex, which consists of several accessory proteins and five small nuclear ribonucleoproteins (snRNPs) [142].”
BackgroundThe RB and p53 pathways in cancer
Sherr, C. J., & McCormick, F. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00102-2 · Cited by 1,690 · cited 1×
“Among these early E2F responsive genes are those of cyclins A and E [166,167].”
BackgroundTreating cancer with selective CDK4/6 inhibitors
O'Leary, B., Finn, R. S., & Turner, N. C. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.26 · Cited by 1,137
Living with or without cyclins and cyclin-dependent kinases
Sherr, C. J., & Roberts, J. M. (2004) · Genes & Development · doi:10.1101/gad.1256504 · Cited by 1,089 · cited 1×
“, growth factors, mitogenic stimuli) cause the release of D-type cyclins (D1, D2, D3) in association with CDK4 and CDK6 initiate further phosphorylation of the retinoblastoma protein family, including pRb, p107, and p130 [10].”
BackgroundDependency of Colorectal Cancer on a TGF-β-Driven Program in Stromal Cells for Metastasis Initiation
Calon, A., Espinet, E., Palomo-Ponce, S., Tauriello, D. V. F., Iglesias, M., Céspedes, M. V., Sevillano, M., Nadal, C., Jung, P., Zhang, X. H.-F., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.013 · Cited by 1,060
Croce, C. M. (2008) · New England Journal of Medicine · doi:10.1056/nejmra072367 · Cited by 1,055
Drugging the ‘undruggable’ cancer targets
Dang, C. V., Reddy, E. P., Shokat, K. M., & Soucek, L. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.36 · Cited by 927
Wada, T., Takagi, T., Yamaguchi, Y., Ferdous, A., Imai, T., Hirose, S., Sugimoto, S., Yano, K., Hartzog, G. A., Winston, F., et al. (1998) · Genes & Development · doi:10.1101/gad.12.3.343 · Cited by 750
Chae, T., Kwon, Y. T., Bronson, R., Dikkes, P., Li, E., & Tsai, L.-H. (1997) · Neuron · doi:10.1016/s0896-6273(01)80044-1 · Cited by 715
A novel cyclin associates with M015/CDK7 to form the CDK-activating kinase
Fisher, R. P., & Morgan, D. O. (1994) · Cell · doi:10.1016/0092-8674(94)90535-5 · Cited by 655
Daub, H., Olsen, J. V., Bairlein, M., Gnad, F., Oppermann, F. S., Körner, R., Greff, Z., Kéri, G., Stemmann, O., & Mann, M. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.07.007 · Cited by 594 · cited 1×
“Early research on CDK10 had demonstrated that this enzyme exerts a positive control on cell division with its function limited to the G2 or M phase of the cell cycle (HeLa S3 cells) [114].”
BackgroundBlazek, D., Kohoutek, J., Bartholomeeusen, K., Johansen, E., Hulinkova, P., Luo, Z., Cimermancic, P., Ule, J., & Peterlin, B. M. (2011) · Genes & Development · doi:10.1101/gad.16962311 · Cited by 522 · cited 1×
“Depletion of the CDK12/CycK complex results in the downregulation of only a small subset of genes (predominantly long and complex ones) and does not affect global transcription rates [140].”
BackgroundcAMP-GEFII is a direct target of cAMP in regulated exocytosis
Ozaki, N., Shibasaki, T., Kashima, Y., Miki, T., Takahashi, K., Ueno, H., Sunaga, Y., Yano, H., Matsuura, Y., Iwanaga, T., et al. (2000) · Nature Cell Biology · doi:10.1038/35041046 · Cited by 481 · cited 1×
“Moreover, CDK5 activity reduces secretion of insulin from pancreatic β-cells in response to a rise in the plasma glucose concentration, which was demonstrated using pancreatic β-cells deficient in p35, an activator of CDK5 [44].”
BackgroundPan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas
Schaub, F. X., Dhankani, V., Berger, A. C., Trivedi, M., Richardson, A. B., Shaw, R., Zhao, W., Zhang, X., Ventura, A., Liu, Y., et al. (2018) · Cell Systems · doi:10.1016/j.cels.2018.03.003 · Cited by 431 · cited 1×
“As MYC governs this many processes, the notion that it could be modulated directly has proven to be difficult [269,270].”
BackgroundArany, Z., Novikov, M., Chin, S., Ma, Y., Rosenzweig, A., & Spiegelman, B. M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603615103 · Cited by 374
Bajrami, I., Frankum, J. R., Konde, A., Miller, R. E., Rehman, F. L., Brough, R., Campbell, J., Sims, D., Rafiq, R., Hooper, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2541 · Cited by 373 · cited 1×
“CDK12 may have a particularly interesting role as a new therapeutic target in oncology as it has been found to be a clinically relevant biomarker of PARP1/2 inhibitor sensitivity as its inhibition acts synthetically lethal with PARP1 inhibition [275].”
BackgroundJohnson, S. F., Cruz, C., Greifenberg, A. K., Dust, S., Stover, D. G., Chi, D., Primack, B., Cao, S., Bernhardy, A. J., Coulson, R., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.10.077 · Cited by 291 · cited 1×
“This suggests that primary and acquired resistance to PARP inhibitors could be overcome by CDK12 inhibition in BRCA wild-type and mutated models of triple negative breast cancer [276].”
BackgroundKrajewska, M., Dries, R., Grassetti, A. V., Dust, S., Gao, Y., Huang, H., Sharma, B., Day, D. S., Kwiatkowski, N., Pomaville, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09703-y · Cited by 281 · cited 1×
“Further analysis indicated that CDK12 directly phosphorylates pre-mRNA processing factors (human neuroblastoma (NB) cells: Kelly, IMR-32, IMR-5, LAN-1, LAN-5, NGP, SK-N-AS, SH-SY5Y, CHLA-20, CHLA-15, and SK-N-FI) [143].”
The cyclin-dependent kinase 8 module sterically blocks Mediator interactions with RNA polymerase II
Elmlund, H., Baraznenok, V., Lindahl, M., Samuelsen, C. O., Koeck, P. J. B., Holmberg, S., Hebert, H., & Gustafsson, C. M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607483103 · Cited by 230
A conserved Mediator–CDK8 kinase module association regulates Mediator–RNA polymerase II interaction
Tsai, K.-L., Sato, S., Tomomori-Sato, C., Conaway, R. C., Conaway, J. W., & Asturias, F. J. (2013) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2549 · Cited by 219
Cdk5-dependent regulation of glucose-stimulated insulin secretion
Wei, F.-Y., Nagashima, K., Ohshima, T., Saheki, Y., Lu, Y.-F., Matsushita, M., Yamada, Y., Mikoshiba, K., Seino, Y., Matsui, H., et al. (2005) · Nature Medicine · doi:10.1038/nm1299 · Cited by 199 · cited 1×
“The inhibitory phosphorylation by CDK5 on the L-type voltage-dependent Ca2+ channel (LVDCC) at Ser783 prevents the binding of L-VDCC to SNARE proteins, thereby preventing exocytosis of insulin from the cell (pancreatic β-cells) (Figure 1) [45].”
BackgroundEWS/FLI confers tumor cell synthetic lethality to CDK12 inhibition in Ewing sarcoma
Iniguez, A. B., Stolte, B., Wang, E. J., Conway, A. S., Alexe, G., Dharia, N. V., Kwiatkowski, N., Zhang, T., Abraham, B. J., Mora, J., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2017.12.009 · Cited by 173 · cited 1×
“Similarly, suppression of wild-type CDK12 in Ewing sarcoma cells driven by the EWS/FLI fusion oncoprotein, a potent transcriptional activator and transforming gene in this disease, using type VI inhibitor THZ531 (a selective covalent inhibitor of CDK12/13) preferentially decreased expression of DDR genes and was syner…”
MethodStructural and functional analysis of the Cdk13/Cyclin K complex
Greifenberg, A. K., Hönig, D., Pilarova, K., Düster, R., Bartholomeeusen, K., Bösken, C. A., Anand, K., Blazek, D., & Geyer, M. (2016) · Cell Reports · doi:10.1016/j.celrep.2015.12.025 · Cited by 157 · cited 1×
“The CDK13/cyclin K heterodimer phosphorylates the highly repetitive carboxy terminal domain (CTD) of RNA polymerase II and participates in gene expression control [299].”
BackgroundXpd/Ercc2 regulates CAK activity and mitotic progression
Chen, J., Larochelle, S., Li, X., & Suter, B. (2003) · Nature · doi:10.1038/nature01746 · Cited by 127 · cited 1×
“Inhibition of CDK7 could simultaneously deprive tumor cells of the high CAK activity required for faithful mitoses [237] and limit the synthesis of mRNAs required for other steps in the cell cycle [238], without affecting global transcription in non-dividing cells.”
BackgroundCheng, S.-W. G., Kuzyk, M. A., Moradian, A., Ichu, T.-A., Chang, V. C.-D., Tien, J. F., Vollett, S. E., Griffith, M., Marra, M. A., & Morin, G. B. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.06267-11 · Cited by 124
A new paradigm in eukaryotic biology: HIV Tat and the control of transcriptional elongation
Barboric, M., & Peterlin, B. M. (2005) · PLoS Biology · doi:10.1371/journal.pbio.0030076 · Cited by 106 · cited 1×
“HIV transcription from the long terminal repeat (LTR) is modulated by the combined activity of cellular initiation factors and the virally encoded regulatory protein, the transcriptional transactivator (Tat) [322,323].”
BackgroundChen, J., Zhang, Y., Kelz, M. B., Steffen, C., Ang, E. S., Zeng, L., & Nestler, E. J. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-24-08965.2000 · Cited by 101 · cited 1×
“The CDK5 gene is located on chromosome 7q36, and its expression is mediated by Fos and CREB transcription factors in the MEK/ERK signaling pathway, as well as by δFosB (human neuroblastoma SK-N-BE(2)C cells) [38,39].”
BackgroundHamilton, M. J., Caswell, R. C., Canham, N., Cole, T., Firth, H. V., Foulds, N., Heimdal, K., Hobson, E., Houge, G., Joss, S., et al. (2018) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2017-104620 · Cited by 43
Metadata
- Authors
- Łukasik, P., Załuski, M., & Gutowska, I.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-03-13
- Volume
- 22
- Issue
- 6
- Pages
- 2935
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3136485825
- Cited by
- 245
- References
- 43
- FWCI
- 10.35
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.